- Home
- OP vs CDIO Comparison
OP vs CDIO Comparison
Compare OP & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- CDIO
- Stock Information
- Founded
- OP 2021
- CDIO 2017
- Country
- OP Greece
- CDIO United States
- Employees
- OP N/A
- CDIO N/A
- Industry
- OP
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- OP
- CDIO Health Care
- Exchange
- OP Nasdaq
- CDIO Nasdaq
- Market Cap
- OP 10.5M
- CDIO 12.3M
- IPO Year
- OP N/A
- CDIO N/A
- Fundamental
- Price
- OP $1.22
- CDIO $0.53
- Analyst Decision
- OP
- CDIO Buy
- Analyst Count
- OP 0
- CDIO 1
- Target Price
- OP N/A
- CDIO $2.00
- AVG Volume (30 Days)
- OP 25.1K
- CDIO 2.5M
- Earning Date
- OP 12-20-2024
- CDIO 11-13-2024
- Dividend Yield
- OP N/A
- CDIO N/A
- EPS Growth
- OP N/A
- CDIO N/A
- EPS
- OP N/A
- CDIO N/A
- Revenue
- OP $25,729,000.00
- CDIO $35,688.00
- Revenue This Year
- OP N/A
- CDIO $2,081.66
- Revenue Next Year
- OP N/A
- CDIO $43.84
- P/E Ratio
- OP N/A
- CDIO N/A
- Revenue Growth
- OP 36.33
- CDIO 180.90
- 52 Week Low
- OP $1.02
- CDIO $0.19
- 52 Week High
- OP $3.15
- CDIO $2.40
- Technical
- Relative Strength Index (RSI)
- OP 44.66
- CDIO 38.70
- Support Level
- OP $1.19
- CDIO $0.49
- Resistance Level
- OP $1.30
- CDIO $0.62
- Average True Range (ATR)
- OP 0.08
- CDIO 0.11
- MACD
- OP 0.01
- CDIO -0.06
- Stochastic Oscillator
- OP 31.43
- CDIO 8.34
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.